NCHR Testimony at the FDA Oncologic Drugs Advisory Committee Meeting on Pediatric Dosage for Cancer Drugs, June 16, 2023

June 16, 2023: NCHR testified on how to choose dosages for pediatric cancer drugs, stating that variables such as weight, age, sex, race, and organ impairment should be studied to identify differences in safety or effectiveness for subpopulations. We also strongly support the specifications about drug safety and tolerability, requiring factors such as duration of exposure and adverse events to be compared across varying dosages.

Read More »

NCHR Comment on USPSTF Draft Research Plan on Weight Loss Intervention

June 14, 2023: Obesity affects nearly half of US adults (42%) and is extremely costly to the US healthcare system, costing $173 billion in 2019. We responded to USPSTF’s request for public comments regarding their research plan, which is aimed at evaluating which pharmaceutical and behavioral treatments for obesity are proven to improve the health of adults, as well as any risks associated with those interventions.

Read More »

NCHR Comments on EPA Per- and Polyfluoroalkyl Substances National Primary Drinking Water Regulation

May 30, 2023: We agree that this proposed rule will improve public health, reducing cancer, heart disease, stroke, low birth weight, and other harms to adults and children. However, we have several recommendations to improve the proposed rule. The PFAS limit should be changed to 2 parts per trillion (ppt) and the EPA needs more explicit limits to prevent a weakening of these regulations. Finally, companies that produce PFAS should bear the financial burden.  

Read More »